Universitas Athena Strati A et al. ngalaporkeun yén naha PD-L1 overexpressed dina sél tumor sirkulasi (CTC) bisa nyadiakeun informasi prognostic leuwih meujeuhna tur penting pikeun penderita sirah na beuheung carcinoma sél squamous. Sanggeus perlakuan, penderita PD-L1 positif dina CTC narima adjuvant terapi suprési PD1 patut evaluasi salajengna. (Ann Oncol. 2017; 28: 1923-1933.)
Based on the tumor’s biological markers, it can be determined whether PD 1 checkpoint inhibitors may ultimately benefit some patients with sirah na beuheung squamous cell carcinoma. The molecular characteristics of circulating tumor cells are critical for studying targeted therapy of tumors, and the biomarkers that predict PD 1 checkpoint inhibitors are still unclear. This prospective study included a group of patients with head and neck squamous cell carcinoma who were being treated to evaluate whether circulating tumor cells that overexpress PD-L1 can be detected at baseline (before treatment) and at different treatment time points to predict treatment After the clinical effect.
Panaliti ngembangkeun kit RT-qPCR anu sénsitip sareng khusus pikeun ngadeteksi ekspresi mRNA PD-L1 dina sél CTC positip EpCAM. Panalitian ngadaptarkeun pasien 113 kalayan karsinoma sél skuamosa sirah sareng beuheung maju lokal sareng ngadeteksi éksprési PD-L1 dina sél CTC positip EpCAM dina dasar, saatos 2 siklus kémoterapi induksi (6 minggu), sareng saatos kemoradiasi sakaligus (minggu 15) Tingkat.
Hasilna nunjukkeun yén dina dasar, 25.5% (24/94) pasien ngagaduhan PD-L1 overexpression di CTCs na. Laju overexpression saatos kémoterapi induksi nyaéta 23.5% (8/34), sareng 22.2% (12/54). Saatos perlakuan, penderita CTC masih overexpressing PD-L1 kagungan salamet bébas-kamajuan anu langkung pondok (P = 0.001) sareng kasadiaan anu langkung pondok (P <0.001).
Saatos perlakuan, PD-L1 tanpa overexpression tiasa janten kamungkinan pikeun ngahontal remisi lengkep (OR = 16, 95% CI 2.76 ~ 92.72; P = 0.002).
